Florida best practice psychotherapeutic medication guidelines for adults with bipolar disorder: A novel, practical, patient-centered guide for clinicians

Journal of Clinical Psychiatry

Volumn 77, Issue 7, 2016, Pages 920-926

  Ostacher, Michael J ^a,b   Tandon, Rajiv ^c   Suppes, Trisha ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; CLOZAPINE; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LURASIDONE; MODAFINIL; OLANZAPINE; PALIPERIDONE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE; PSYCHOTROPIC AGENT;

ACUTE DISEASE; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CONSENSUS; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; FLORIDA; MAINTENANCE THERAPY; MANIA; MONOTHERAPY; PATIENT PREFERENCE; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; TRANSCRANIAL MAGNETIC STIMULATION; COMBINATION DRUG THERAPY; HUMAN; PATIENT CARE; STANDARDS;

BIPOLAR DISORDER; DRUG THERAPY, COMBINATION; FLORIDA; HUMANS; PATIENT-CENTERED CARE; PSYCHOTROPIC DRUGS;

EID: 84980378186     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15cs09841     Document Type: Article

References (32)

1. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4 suppl):1-50.
2. Brouwers MC, Kho ME, Browman GP, et al; AGREE Next Steps Consortium. AGREE II: Advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol. 2010;63(12):1308-1311.
3. Castellani A, Girlanda F, Barbui C. Rigour of development of clinical practice guidelines for the pharmacological treatment of bipolar disorder: systematic review [published online ahead of print November 25, 2014]. J Affect Disord. 2015;174:45-50.
4. Fountoulakis KN, Kasper S, Andreassen O, et al. Efficacy of pharmacotherapy in bipolar disorder: A report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci. 2012;262(suppl 1):1-48.
5. Institute of Medicine. Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies Press; 2011.
6. Knai C, Brusamento S, Legido-Quigley H, et al. Systematic review of the methodological quality of clinical guideline development for the management of chronic disease in Europe. Health Policy. 2012;107(2-3):157-167.
7. Suppes T, Dennehy EB, Swann AC, et al; Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. Report of the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder 2000. J Clin Psychiatry. 2002;63(4):288-299.
8. Department of Veterans Affairs, Department of Defense. VA/DoD clinical practice guideline for clinical management of bipolar disorder in adults; guideline summary. Version 2.0. 2010. http://www.healthquality.va.gov/guidelines/MH/bd/bd-306-sum.pdf. Updated May 2010. Accessed June 17, 2015.
9. Hirschfeld R. Guideline Watch for the Practice Guideline for the Treatment of Patients With Bipolar Disorder. Arlington, VA: American Psychiatric Association; 2002.
10. Ostacher MJ. Raising the bar for the evidence in evidence-based guidelines. Bipolar Disord. 2013;15(1):50-53.
11. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1-44.
12. NICE Guidelines. Bipolar disorder: The assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. NICE Web site. http://www.nice.org.uk/guidance/cg185. Updated September 2014. Accessed June 1, 2015.
13. Constantine RJ, Andel R, Tandon R. Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program. Community Ment Health J. 2010;46(6):523-530.
14. Constantine RJ, McPherson MA, Jones ME, et al. Improving psychotherapeutic medication prescribing in Florida: implementation of the Florida Medicaid Drug Therapy Management Program (MDTMP). Community Ment Health J. 2013;49(1):33-44.
15. Florida Medicaid Drug Therapy Management Program for Behavioral Health. About us. http://medicaidmentalhealth.org/aboutus/. Accessed January 7, 2015.
16. Cosgrove VE, Suppes T. Informing DSM-5: biological boundaries between bipolar I disorder, schizoaffective disorder, and schizophrenia. BMC Med. 2013;11(1):127.
17. Tandon R. Bipolar and depressive disorders in DSM-5: clinical implications of revisions from DSM-IV. Indian J Psychol Med. 2015;37(1):1-5.
18. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160-168.
19. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):169-177.
20. Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: A meta- Analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013;10(3):e1001403.
21. van der Loos ML, Mulder PG, Hartong EG, et al; LamLit Study Group. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: A multicenter, doubleblind, placebo-controlled trial. J Clin Psychiatry. 2009;70(2):223-231.
22. Bailine S, Fink M, Knapp R, et al. Electroconvulsive therapy is equally effective in unipolar and bipolar depression. Acta Psychiatr Scand. 2010;121(6):431-436.
23. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249-1262.
24. Sachs GS, Ice KS, Chappell PB, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(10):1413-1422.
25. Calabrese JR, Frye MA, Yang R, et al; Armodafinil Treatment Trial Study Network. Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: A randomized, double-blind, placebocontrolled, multicenter trial. J Clin Psychiatry. 2014;75(10):1054-1061.
26. Calabrese JR, Ketter TA, Youakim JM, et al. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: A randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010;71(10):1363-1370.
27. Sachs GS, Vanderburg DG, Karayal ON, et al. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: Results of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2012;73(11):1412-1419.
28. Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev. 2014;10:CD010236.
29. Vieta E, Nuamah IF, Lim P, et al. A randomized, placebo- And active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord. 2010;12(3):230-243.
30. Yatham LN, Fountoulakis KN, Rahman Z, et al. Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. J Affect Disord. 2013;147(1-3):365-372.
31. Berwaerts J, Lane R, Nuamah IF, et al. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: A randomized, placebo-controlled study. J Affect Disord. 2011;129(1-3):252-260.
32. Berwaerts J, Melkote R, Nuamah I, et al. A randomized, placebo- And active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J Affect Disord. 2012;138(3):247-258.